I am working with debilitated mice and exploring the protective effects of carnosic acid on the kidneys and vascular endothelium in the context of sepsis-induced acute kidney injury, specifically via the TLR4/NF-κB/NLRP3 pathway. However, I am facing challenges with carnosic acid exceeding its solubility limit.
Given that the DMSO content must remain below 2% and the maximum dose of carnosic acid can be as high as 200 mg/kg, what strategies or formulations could I use to effectively manage this issue? Any insights or recommendations based on your experiences would be greatly appreciated!
Currently, two formulations have demonstrated relatively high solubility in testing:
(1) 0.5% CMC-Na/saline water, 10mg/mL, suspension.
(2) 15% Cremophor EL + 85% Saline, 10mg/mL, clear solution.
Formulation 2 is not recommended for treatment cycles exceeding two weeks. The suspension can be administered via intraperitoneal injection or oral gavage.
Additionally, Carnosic acid (HY-N0644), a commonly used dosage in animal studies is 20mg/kg. It is advisable to refer to the experimental protocols described in the literature when determining administration procedures.
Reference: PMID: 15050633
The answer to this question is provided by MedChemExpress Technical Support.
- Badges
- Science method